Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Rhea-AI Summary

Axcella Therapeutics (Nasdaq: AXLA) announced it will present clinical data on plasma proteomic biomarkers for NASH at the AASLD Annual Meeting in Washington, D.C., from November 4-8, 2022. The presentation, titled Identifying Predictive Plasma Proteomic Biomarkers for Clinical™ Response to AXA1125, will occur on November 5, 2022, during a poster session. This research aims to enhance understanding of treatment responses using Axcella's innovative endogenous metabolic modulators (EMMs), which are designed to address complex diseases including NASH.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.

Presentation Details

Title: Identifying Predictive Plasma Proteomic Biomarkers for Clinical™ Response to AXA1125: An Endogenous Metabolic Modulator (EMM) Composition Being Developed for the Treatment of NAFLD/NASH

Session Type: Poster Session #2000 – 2999

Abstract Number: 2511

Date and Time: Saturday, November 5, 2022, 1:00 PM – 2:00 PM (ET)

Please come visit members of the Axcella team at Booth #444.

With 8,000 attendees The Liver Meeting is the world’s premier meeting on liver disease. Over the course of 5 days clinicians and scientists from around the world exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology. Attendees include:

• Adult and pediatric hepatology experts
• Clinical, basic, and translational researchers
• Specialists who diagnose and treat liver disease, including gastroenterologists, surgeons, clinical pathologists, anesthesiologists, and radiologists
• Primary care physicians
• Nurse practitioners, registered nurses, physician assistants, pharmacists, and other allied health professionals in hepatology and the disciplines listed above
• Patient advocates and patients

Internet Posting of Information

Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID, NASH, and the reduction in risk of OHE recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005856/en/

Ashley Robinson

arr@lifesciadvisors.com

(617) 775-5956

Source: Axcella Therapeutics

FAQ

What will Axcella Therapeutics present at the AASLD Annual Meeting?

Axcella Therapeutics will present data on plasma proteomic biomarkers for NASH on November 5, 2022.

When is the AASLD Annual Meeting where AXLA will present?

The AASLD Annual Meeting is scheduled for November 4-8, 2022.

What is the title of the presentation by Axcella Therapeutics?

The presentation is titled Identifying Predictive Plasma Proteomic Biomarkers for Clinical™ Response to AXA1125.

Where can I find more information about Axcella Therapeutics and its research?

Additional information can be found on Axcella Therapeutics' website at www.axcellatx.com.

What is AXA1125 being developed for?

AXA1125 is being developed as an endogenous metabolic modulator for the treatment of NAFLD/NASH.